CANTON, Mass. — Collegium Pharmaceutical, the scrappy upstart taking on the mighty opioid maker Purdue Pharma, is having a moment.

The company recently convinced Cigna, Humana, Navitus, and top health insurers in Florida and Pennsylvania to cover only its product Xtampza — and not Purdue’s infamous OxyContin — for most patients prescribed the long-acting opioid known to scientists as oxycodone. Earlier this month came another win: The Food and Drug Administration agreed to let Collegium update Xtampza’s label to describe data demonstrating that the capsules are harder than OxyContin to abuse when crushed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy